Eli Lilly and Company Research Report - FY2023 Q3

FY2023 Q3: Underlying Revenue Growth Accelerates to 24%; EPS Guidance Cut on $3B in Acquired IPR&D Charges

Sign in required

Sign in or create an account to continue to this document.

Pic
dbot